Skip to main content

Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membership to eight. Ms. Dao-Haddock is a certified public accountant (CPA) with more than 20 years of financial and accounting experience. She will serve on Biocept’s Audit Committee.

“Quyen’s extensive financial experience leading accounting and finance departments, and overseeing technical accounting, budgeting and forecasting, financial modeling, cash management and SEC reporting, make her a valuable addition to our Board and its Audit Committee,” said Samuel D. Riccitelli, Biocept’s Chairman, and interim President and CEO. “We expect Quyen will make significant contributions as we seek standard-of-care status for our proprietary cerebrospinal fluid assay CNSide™ and focus on delivering value to our stockholders.”

“It’s an exciting time to join the Biocept Board as the Company directs its resources toward providing valuable information to improve clinical outcomes for patients with cancer and central nervous system involvement, who oftentimes have extremely poor prognoses,” said Ms. Dao-Haddock. “I’m delighted to utilize my skills and expertise to support the advancement of CNSide and the Company’s diagnostic programs.”

Ms. Dao-Haddock serves as controller of IQHQ, Inc., a $2.5 billion start-up real estate investment trust (REIT) focused on the life sciences industry, with responsibility for scaling the accounting and finance department and establishing and implementing comprehensive accounting policies. She previously was Chief Accounting Officer of Presidio Property Trust, Inc., where she was responsible for all financial and accounting operations of this REIT with more than $30 million in annual revenues and $200 million in assets. Earlier she was Corporate Controller of American Assets Trust, Inc., an NYSE-listed REIT with more than $315 million in annual revenues and $2 billion in assets, and Controller at Pacific Corporate Group, LLC, a private equity firm with $30 million in revenue and $16 billion in assets. She began her career as an Audit Manager at KPMG LLP.

Ms. Dao-Haddock serves on the Audit & Compliance Committee of Sharp HealthCare. She received a BS in Business Administration, Accounting from San Diego State University.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. For more information, visit Follow Biocept on Facebook, LinkedIn, Twitter, and Instagram.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," “goal,” or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this press release are not strictly historical, including, without limitation, statements regarding our ability to establish CNSide as the new standard-of-care diagnostic test for patients with metastatic cancer that has spread to the central nervous systems, and the ability of our products, including CNSide, to provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including risks and uncertainties associated with the ability of our products to compete successfully with competitive products or treatments; our ability to obtain and maintain adequate reimbursement for our products; and the risk that our products and services may not perform as expected. These and other factors are described in greater detail under the "Risk Factors" heading of Biocept’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the SEC on November 10, 2022. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this press release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at


Investor and Media Contact:

Jody Cain, LHA Investor Relations, 310-691-7100

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.